Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Mar 10, 2022 2:51pm
163 Views
Post# 34503996

RE:RE:RE:Treated Patients 13 to 30

RE:RE:RE:Treated Patients 13 to 30
Great conversation everyone. I just wanted to say that the patient tracker is almosr 100% based on the most recent newsletter. I just did the following:

- pluggedin the optimized patients as that is easy.

https://postimg.cc/jLWvsJRp

- then added in phase1b patient trio.

https://postimg.cc/yWGXrY0v

- finally, played with the spreadsheet to make the 33 total patients from the newsletter, make sense given the optimized and the 1b patient trio. In doing this I had to make some guesses. For example, to make the PR and CR numbers make sense at 180 days I assumed that one CR converted to a PR. Then to make it work at 270, one the NR totals only worked if we assumed that the PR patient converted to NR. And so forth. Really kind of like a soduku or wordle puzzle.

https://postimg.cc/XXr9FStF

I would really really love it if someone would duplicate the process from scratch from November newsletter to see if I made a mistake in assumptions. Takes half an hour to do.

As a final comment TLT sometimes posts data in a way that doesn't make sense math-wise so I think they are still error prone on their end. For example, looking at the new corp slide deck, I can't make sense of the math on slide 11, right sided image. The only way that it work is if the 90 day patient total is 18 but the 180,270,360,450 group size is 22 (not 18 which is what TLT says is the total in the newsletter itself). To add to the confusion the right side image says 33 on it.

https://postimg.cc/1nq6kDGB

So some of our challenges may be on the data we are working from.

Cheers.
<< Previous
Bullboard Posts
Next >>